Topic: Coronavirus: Impacts on Dealmaking and Powerful Tools for Getting Ahead

Rachael Craig, CEO at MotionHall: Good morning, everyone! Thank you for joining us today in the latest in MotionHall’s Executive Series of webinars. This is the third in a series of discussions addressing impacts of the coronavirus on …

Introduction

Rachael Craig, MotionHall: Glad to be hosting us today! My name is Rachael Craig, and I’m MotionHall’s Co-Founder and CEO. MotionHall exists for one reason, and that’s to help you ensure your company closes the most valuable licensing or M&A deal possible. We're very pleased …

Introduction

Rachael Craig, MotionHall: Good morning Chris! Thanks for joining us on our latest in our series of executive webinars from MotionHall.

This is the first of several special editions focused on the unique times we find ourselves in, and I’m very pleased this morning to have Chris Garabedian …

Introduction

Rachael Craig, MotionHall: Thanks for joining us on our latest in our series of executive webinars from MotionHall.

This is the second of several special editions focused on the unique times we find ourselves in, and I’m very pleased that today, Anton Gueth from EVOLUTION Life Sciences Partners …

Introduction

Rachael Craig: Good morning everyone! Thank you for joining us today in the latest in our very well attended series of executive webinars from MotionHall.

We get really great feedback on these executive calls and we tend to cover a lot of material that isn't addressed elsewhere, which makes …

Executive Call Series: OutMatch Best Practices for Navigating Large Pharmas. All Levels. February 5th, 2020 - session presented twice with different discussion, North America & APAC Time Zones. Q&A excerpt from transcribed notes, lightly edited.

Audience Question:

Rachael Craig, CEO at MotionHall: The first question that I have today, one that …

The 2019 Benchmarking Pharma Partnering in Europe report outlines how deals are flowing in Europe, noting partnerships in this region don’t come without their costs.

A look at the risks and rewards in the European market

We analyzed 43 pharmaceutical licensing deals between January 2012 and August 2019, in …

Learn how to maximize biopharma deal value

How does a licensing deal emerge? How does it proceed to signing?

Anatomy of an Out-licensing Deal identifies and describes 15 key steps seen in successful licensing transactions.

This white paper will be insightful for:

• • Newcomers to the biotech or pharmaceutical industries.
• • Those already working in biopharma, but not focused on the details of dealmaking.
• 
  
  Read More

Transcribed notes lightly edited. Executive Call Series: How to build a solid BD Strategy. All Levels. August 13, 2019, Tuesday, 8:00 - 8:30 AM

Introduction

Erin: Good morning everyone. You might not be able to speak if you're muted, but hopefully, you can all hear me. If not, you …

The secret to licensing success is to have your plan in place years in advance. In fact, many companies consider business development before capital investment occurs, either in the company or in an individual program.

When should my biotech company consider licensing strategy? The answer is, as early as possible …

Maximize Your Biopharma Deal Value

How to Create a Solid Biotech Business Development Strategy is written exclusively for emerging biopharma dealmakers.

Chinese licensing partnerships are becoming both more common and more valuable, but the overall deal value for China remains relatively small.

Rare insight into the costs and opportunities in the Chinese market

We analyzed 92 licensing deals for pharmaceutical products in which China was the major territory for a foreign …

“Under the terms of the agreement, AC Immune will receive an upfront payment of CHF80 million as well as $50 million in exchange for a note, convertible to equity at a premium.”

The BIO International conference presents an incredible opportunity to connect, build relationships and conduct business.

AbbVie's last deal of 2017 and first deal of 2018, both in Alzheimer's Disease and other neurodegenerative disorders, could mean that they are considering the vacuum left by Pfizer's neuroscience exit.

In our July 2017 profile of Gilead Sciences, we commented on their need to develop or acquire new blockbuster drugs. One month later, they did just that.

Here’s the thing - Most of those companies aren’t going to transact. They were never going to transact. And a thoughtful analysis would have shown you they weren’t going to transact before your team wasted months of executive time and company dollars flying to conferences and pointless meetings.

Artificial Intelligence provides opportunities to better understand and engage in a world saturated with data; empowering dealmakers to more deeply leverage their relationship expertise.

Our team at MotionHall has translated one of the software industry’s most powerful sales practices, predictive analytics, to the life sciences business development process.

We call it predictive dealmaking, and it’s the smartest and easiest way to win biopharma deals thanks to MotionHall’s powerful OutMatch AI.

Read on to find out more about predictive dealmaking and how it benefits your licensing process.

Gilead Sciences, Inc.
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: $9809M USD
Therapeutic Focus: HIV/AIDS, Liver Diseases, Hematology/Oncology, Inflammation/Respiratory, Infectious Diseases

Perhaps the best way to describe yesterday’s session on immuno-oncology, is to start at the end.

Just as the applause faded, the audience en masse rushed to the panelists, business cards in hand, hoping the brief exchange might lead to a transaction in the hottest area of biotech these days. And it could.

Oncology is dominating both interest from buyers and sellers in the marketplace, according to Neel Patel, Managing Director at Campbell Alliance, an inVenitv Health Company. That was one of the big takeaways from BIO's Tuesday Dealmakers’ Intentions: 2017 Market Outlook session.

“It’s not surprising to see the focus on oncology,” Dr. Paul Biondi, head of Business Development, Bristol-Myers Squibb, said.

“The company was a black box to me because I allowed my banker to actually deal with the company,” he said. And he hadn’t formed relationships with the senior officials of the company - people he could have called upon to try and salvage the deal.

Hasnain never made the same mistake again.

“It’s all about the relationships.”

Leading dealmakers understand that the challenge is not just to find a partner, but the right partner — one who will contribute to investor confidence and long-term success, more than immediate capital.

Here’s how they do it: